Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $85.33 Average Price Target from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $85.3333.

Several research analysts have recently issued reports on PBH shares. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target for the company in a research note on Wednesday, September 24th. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the transaction, the vice president owned 42,329 shares in the company, valued at approximately $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. lifted its position in shares of Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after buying an additional 144 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Prestige Consumer Healthcare by 2.0% during the 2nd quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock worth $747,000 after acquiring an additional 182 shares during the last quarter. Profund Advisors LLC raised its stake in Prestige Consumer Healthcare by 3.2% in the 3rd quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after acquiring an additional 207 shares during the period. Cerity Partners LLC lifted its holdings in Prestige Consumer Healthcare by 5.9% during the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after purchasing an additional 218 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in Prestige Consumer Healthcare by 312.5% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Up 1.3%

Shares of PBH opened at $65.60 on Tuesday. The company has a quick ratio of 2.51, a current ratio of 3.70 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $61.31 and a two-hundred day moving average price of $65.44. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of 16.28, a P/E/G ratio of 2.03 and a beta of 0.40. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. The business had revenue of $274.11 million for the quarter, compared to analyst estimates of $257.14 million. During the same quarter in the prior year, the firm earned $1.09 EPS. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).